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Background: For therapeutic monitoring and pharmacokinetic studies of lenalidomide (LND), the potent drug for
treatment of multiple myeloma (MM), a specific antibody was required for the development of a sensitive
immunoassay system for the accurate determination of LND in plasma.
Results: In this study, a hapten of LND (N-glutaryl-LND) was synthesized by introducing the glutaryl moiety, as a
spacer, into the primary aromatic amine site of the LND molecular structure. The structure of the hapten (G-LND)
was confirmed by mass, 1H-NMR, and 13C spectrometric techniques. G-LND was coupled to each of bovine serum
albumin (BSA) and keyhole limpet hemocyanin (KLH) proteins by ethyl-3-(3-dimethylaminopropyl) carbodiimide as a
coupling reagent. LND-KLH conjugate was used as an immunogen. Four female 2-3 months old New Zealand
white rabbits were immunized with an emulsion of LND-KLH with Freund`s adjuvant. The immune response of the
rabbits was monitored by direct enzyme-linked immunosorbent assay (ELISA) using LND-BSA immobilized onto
microwell plates as a solid phase. The rabbit that showed the highest antibody titer and affinity to LND was
scarified and its sera were collected. The IgG fraction was isolated and purified by affinity chromatography on
protein A column. The specificity of the purified antibody for LND was evaluated by indirect competitive ELISA
using dexamethasone as a competitor as it is used with LND in a combination therapy.
Conclusions: The high affinity of the antibody (IC50 = 10 ng/mL) will be useful in the development of an
immunoassay system for the determination of plasma LND concentrations. Current research is going to optimize
the assay conditions and validate the procedures for the routine application in clinical laboratories.
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Pharmacokinetic studiesBackground
Cancer is one of the greatest health concerns, as it is the
principal cause of mortality among men and women
worldwide; it accounted for 7.4 million deaths (around
13% of all deaths each year). Deaths from cancer world-
wide are projected to continue rising, with an estimated
12 million deaths in 2030 [1]. Multiple myeloma (MM)
is a B-cell malignancy characterized by proliferation of
monotypic plasma cells. It is the second most common* Correspondence: idarwish@ksu.edu.sa
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distribution, and reproduction in any mediumhematological malignancy; approximately 20,000 cases of
MM have been diagnosed in 2007 [2].
The hallmark of MM is the production of a homoge-
neous immunoglobulin fraction, called myeloma protein,
by the malignant plasma cells [3]. Pathologic bone dam-
age is the most characteristic feature of MM and is
caused by the production of osteoclastic factors by the
malignant plasma cells. Bone pain is the predominant
presenting symptoms, but other symptoms such as
anemia, hypercalcemia, renal insufficiency, neuropathy,
and spinal cord compression may be present at the time
of diagnosis. The classical triad of symptoms is plasmacytosistral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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protein either in the urine or blood, and lytic bone
lesions [3,4]. MM is ultimately fatal with most patients
relapsing after an initial response to the conventional
chemotherapy. Autologous stem cell transplantation
and melphalan have prolonged overall survival rates in
patient populations, but most individuals eventually
succumb to a refractory form of the disease.
In the 1990s, thalidomide (ThalomidW, Celgene Cor-
poration) was used empirically in treatment of MM
based on its antiangiogenic activity and clinical activity
in refractory or relapsed myeloma [5]. However, thalido-
mide has significant and dose-limiting somnolence, con-
stipation, neuropathy, and teratogenicity [6]. These toxic
effects promoted the search for more potent but less
toxic thalidomide derivatives [7]. Lenalidomide (LND) is
a potent novel thalidomide analog which demonstrated
remarkable clinical activity against myeloma cells [8-12]
via a multiple-pathways mechanism [7,13-17]. The strong
evidences-based clinical success of LND in patients has
led to its recent approval by US-FDA under the trade
name of RevlimidW capsules by Celgene Corporation [18].
Lenalidomide has a more improved side effects profile
than its parent compound thalidomide, nevertheless,
it causes some dose-dependent side effects such as
thrombocytopenia, venous thromboembolism, and myelo-
suppression [19,20]. These side effects can be managed by
combination therapy and/or careful dose adjustment
[21,22]. Because LND is primarily excreted via kidneys,
patients with renal insufficiency or failure must be dose
adjusted to prevent the exacerbation of its myelosuppres-
sive effects [9,16]. Because of the structural relation of
LND to thalidomide, a teratogenic effect can not ruled
out, thus effective contraception must be used by female
patients [23,24]. Furthermore, studies showed large inter-
individual pharmacokinetic variability with concentra-
tion–toxicity relationship [25]. For these reasons, a risk
management, monitoring blood counts, and therapeutic
drug monitoring are required to achieve the highest thera-
peutic benefits of LND and prevent its fatal complications
[8,26,27]. Nevertheless, the therapeutic profile of LND is
anticipated to encourage the development of new pharma-
ceutical preparations for LND. As a consequence, there
is an increasing demand for proper analytical technolo-
gies for determination of pharmacokinetic parameters
in bioequivalence studies for LND, as well as in its
therapeutic monitoring.
Extensive literature survey showed that there were
only two methods for the determination of LND in
plasma [28,29]. These two methods involved liquid
chromatography-coupled with mass spectrometric detec-
tors. These two methods offered adequate sensitivities;
however they employed the expensive mass detectors
that are not available in most laboratories, and involvedlaborious liquid-liquid sample extraction procedures that
negatively affected the accuracy of the results. Further-
more, these methods, as relied on sequential samples
analysis, are not suited for screening of large number of
specimens. Accordingly, the development of a new alter-
native analytical technology for the determination of
LND in plasma with adequate sensitivity, improved sim-
plicity, lower cost, and higher throughput is urgently
needed.
Immunoassays are preferable in the field of clinical
analysis because of their applicability for a wide range of
analytes, high-throughput, low cost, convenience for
screening of a large number samples, and their specifi-
city for the analyte of interest even in multi-component
complex sample matrix such as plasma [30]. The anti-
body is the most important key reagent in the develop-
ment of any immunoassay system. As well, specificity of
the antibody to the analyte of interest is the limiting
factor in the validity of the assay. In order to establish a
specific and sensitive immunoassay for LND, a specific
antibody with high affinity for LND was required. The
present study describes, for the first time, the synthesis
of hapten for LND (modified LND with a 5-carbon
glutaryl moiety as a spacer, and capable for direct linking
to a protein) and preparation of a polyclonal antibody
that can specifically recognizes LND with high affinity.
This antibody will be useful for the establishment of a
specific immunoassay for the determination of plasma
LND concentrations. Optimization of the assay conditions
and validation of the method for the routine application in
clinical laboratories will be published elsewhere.
Experimental
Apparatus
Microplate/cuvette reader (Spectramax M5, Molecular
Devices, California, USA). Automatic microplate strip
washer (MW-12A, Bio-Medical Electronics Co. Ltd.,
Shenzhen, China). EM-36N microtube shaker (Taitec,
Japan). Biofuge Pico centrifuge (Heraeus Instruments,
Germany). Incubator (KARL KOLB, Scientific Technical
Supplies, Dreieich, Germany). Microprocessor laboratory
pH meter (Mettler-Toledo International Inc., Zürich,
Switzerland). Direct reading balance (XB 120A, Precisa
Instruments Ltd., Switzerland). UV–vis Spectrophotometer
(V-530, JASCO, Tokyo, Japan). Water purification (distilla-
tion apparatus, D-30938, GFL, Burgwedel, Germany).
HPLC apparatus consisted of a Shimadzu system (Shi-
madzu Corporation, Kyoto, Japan) equipped with LC-
10AD VP pump with FCV-10AL VP low pressure flow
control valve, SCL-10A VP system controller, Rheodyne-
7725 injection valve with variable loops, SPD-10A VP UV-
visible detector, and RF-10A XL fluorescence detector.
The system control and data acquisition are performed by
Shimadzu CLASS-VP software, version 5.032 (Shimadzu
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was conducted at the Department of Pharmaceutical
Chemistry, College of Pharmacy, King Saud University,
Saudi Arabia on Agilent Ion Trap 6320 LC/MS (Agilent
Technologies, Saugus, MA, USA. NMR Spectra were
scanned in DMSO-d6 on a Bruker NMR spectrophotometer
operating at 500 MHz for 1H and 125.76 MHz for 13C
at the research center, College of Pharmacy, King Saud
University, Saudi Arabia. Chemical shifts were expressed
in δ-values (ppm) relative to TMS as an internal standard.
D2O was added to confirm the exchangeable protons
Materials
Lenalidomide (LND) was obtained from LC Laboratories
(Woburn, USA). Horseradish peroxidase labeled goat
anti-rabbit IgG (HRP-IgG), bovine serum albumin (BSA),
2,4,6-trinitrobenzene sulfonic acid, 1-ethyl-3-(3-dimethy-
laminopropyl) carbodiimide hydrochloride (EDC), 3,3`,
5,5`-Tetramethylbenzidine (TMB) peroxidase substrate,
glutaric anhydride, and Freund's adjuvants (complete and
incomplete) were purchased from Sigma Chemical Co.
(St. Louis, MO, USA). Keyhole limpet hemocyanin (KLH)
was purchased from Novabiochem Co. (La Jolla, CA,
USA). BCA protein assay kit was purchased from Pierce
Chemical Co., Rockford, USA). ELISA high-binding
microwell plates were a product of Corning/Costar, Inc.
(Cambridge, MA, USA). Dialysis tubes were from Sigma
Chemical Co., St. Louis, MO, USA). All other chemicals
and solvents used throughout the work were of analytical
grade.
Procedures
Synthesis of hapten (N-Glutrayl Lenalidomide; G-LND)
Lenalidomide (130 mg, 0.5 mmole) was added to glutaric
anhydride (57 mg, 0.5 mmole) dissolved in 10 mL of
benzene. The reaction was allowed to proceed under
reflux for 24 hours. The reaction was monitored by HPLC
system to confirm the formation of N-glutaryl LND. The
chromatographic conditions were; reversed phase column
(Nucleosil C8, 150 × 4.6 mm, 5 μm), isocratic elution by a
mobile phase consisted of 20% acetonitrile containing
0.1% trifluoroacetic acid, and the flow rate was set at
1 mL/min. The eluted peaks were detected by UV detector
at 254 nm. After completing the reaction, the N-glutaryl
LND (G-LND) was purified by crystallization from etha-
nol. The purity of the product was confirmed by HPLC
system. The chemical structure of the purified G-LND was
confirmed by mass, 1H-NMR, and 13 C spectrometric
techniques.
Preparation of LND protein conjugates
Fifty milligrams of G-LND (hapten) was dissolved in
dimethylformamide. To this solution, 100 mg of EDC
was added, and the pH was rapidly adjusted to 5–5.5with 0.01 M HCl. After 5 min, the protein (BSA and
KLH) solution (5 mg/mL) was added. Protein solutions
were prepared by dissolving 50 mg of each of BSA and
KLH in 5 mL of 50 mM phosphate buffer (PB) of pH
7.2. After addition of the protein solution, the pH of the
reaction mixture was rapidly adjusted to 6.4 and main-
tained constant for 90 min. The reaction was left over-
night in the dark at 4°C. The residual unreacted small
LND hapten molecules were removed from the LND-
protein conjugates by dialysis. The degree of conjugation
of LND to each of BSA and KLH was then estimated by
protein assay and UV spectral analysis [31].
Immunization of animals, preparation and purification of
anti-LND antibody
Four rabbits were subjected to the immunization by
LND-KLH conjugate. The immunization protocol, and
monitoring the immune response of the animals have
been conducted according to the procedures described
by Darwish et al. [32]. The affinities of the raised anti-
bodies to LND were determined by a competitive ELISA
described by Darwish et al. [32]. The antibody that
showed the highest affinity to LND was purified by affinity
chromatography on protein A column.
Results and discussion
Synthesis and structure confirmation of LND Hapten
(N-Glutaryl-LND)
Since LND is small molecule, it is not naturally im-
munogenic, and hence it does not elicit an immune
response unless coupled with some macromolecules
such as proteins. It was, therefore, required to modify
LND for coupling with carrier protein so as to make a
stable LND-protein conjugate. LND has a primary aro-
matic amino group via which LND could be directly
conjugated with proteins by a well-established procedure
of diazotization of the aniline group and conjugation to
the tyrosine residues of the proteins [33]. However, it
was reported that the introducing of a “spacer group”
between the drug molecule and the carrier protein usu-
ally increases the specificity of the produced antibody
[34]. Therefore the introducing a glutaryl moiety into
the LND structure via its aniline group was attempted.
This spacer (5 carbon atoms) was anticipated to be
adequately spaced from the LND epitopic moiety [34].
Glutaryl residue was introduced into LND by reaction
with glutaric anhydride (Figure 1), and as expected, two
peaks appeared in the chromatogram of the reaction
mixture (Figure 2). The firstly eluted peak showed reten-
tion time similar to that of LND (4.5 min) indicating
that this peak corresponded to the unreacted LND. The
second peak (at retention time of 7.8 min) was thought
to be glutaryl-LND derivatives. LC/MS spectrometry for




















Figure 1 Preparation of LND-protein conjugates. EDC is ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, and R−NH2 is the BSA
and KLH proteins.
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the reaction, the product was purified and its structure
was confirmed by 1H-NMR and 13C spectrometry
(Figure 3).
The 1H NMR spectrum (DMSO-d6) of the product is
given in Figure 3A. δ 1.81-1.84 (m, 2H, -CH2-CH2
-COOH of glutaryl moiety) 2.2-2.6(m, 4H, -CH2-CH2-of
piperidine ring), 3.4 (t, 4H,-CH2-CH2-CH2-COOH),
4.32-4.38, 4.35-4.4 (dd, J=32Hz, -CH2-N- of pyrrolidone
ring), 5.16 (t, 1H, J=9, -CH of piperidine ring), 7.4-7.8
(m, 3H, ArH), 9.8 (s, 1H, NH, of the amide side chain,
D2O exchangeable), 11.04 (s, 1H, NH of piperidine ring,
D2O exchangeable), 12.13 (s, 1H, -COOH, D2O ex-
changeable). The figure depicts the aromatic protons
part of the1H NMR spectrum and the three D2O ex-
changeable protons of the synthesized compound (two
NH and one COOH protons).LND
RM
Figure 2 Chromatogram of standard LND and its reaction
mixture (RM) with glutaric anhydride. Chromatographic
conditions are: reversed phase column (Nucleosil C8, 150 × 4.6 mm,
5 μm), isocratic elution by a mobile phase consisted of 20%
acetonitrile containing 0.1% trifluoroacetic acid, the flow rate was set
at 1 mL/min, the detection was UV at 254 nm.The 13C spectrum of the product is given in Figure 3B:
δ 18.5 (−CH2-CH2-COOH of glutaryl moiety), 20.3
(−CH2-CH2-C=O of piperidine ring), 22.5 (−CH2-CH2
-C=O of piperidine ring), 31.1 (−CH2-CH2-COOH), 32.9
(−CH2-CONH of glutaryl moiety), 34.8 (−CH2-N- of
pyrrolidone ring), 55.9 (−CH of piperidine ring), 118.9,
125.2, 128.5-132.6, 133.6 (−CH Aromatic), 167.8 (−CH
-C=O of piperidine ring), 171 (−CH2-C=O of piperidine
ring), 172.8 (−COOH), 174.1 (C=O amide of glutaryl
moiety). Upon comparing these data with those of the
starting material (standard LND), it was clear the differ-
ence between LND and the synthesized compound at
the upfield region of the spectra indicating the aliphatic
part of the side chain as well as the appearance of new
two signals downfield indicating the presence of C=O
carboxylic acid and C=O amide.
Preparation and characterization of LND-Protein
conjugates
The hapten (G-LND) was used for its linking to carrier
proteins. Bovine serum albumin (BSA) and keyhole limpet
hemocyanin (KLH) proteins were selected as carrier pro-
teins because they are rich in lysine residues that can
couple with the carboxylic moiety of the G-LND [35].
Linking of G-LND with BSA and KLH proteins was
achieved by carbodiimide method [36] as illustrated in
Figure 1.
In order to ascertain the conjugation and estimate the
extent to which G-LND was conjugated to the proteins,
spectral analysis for the LND-protein conjugates were
conducted. Under the same conditions, the UV absorp-
tion spectra of the LND-protein conjugates, the uncon-
jugated hapten (G-LND), and the proteins were
recorded. The spectra that have been generated in case
of BSA conjugate are given in Figure 4, and similar
results were obtained with KLH protein. Obviously, the
absorbances of the LND-protein conjugates were higher
Figure 3 (See legend on next page.)
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Figure 3 1H-NMR (A) and 13C (B) spectra of glutaryl-LND derivative. NMR Spectra were scanned in DMSO-d6 on a Bruker NMR spectrometer
operating at 500 MHz for 1H and 125.76 MHz for 13C. Chemical shifts are expressed in δ-values (ppm) relative to TMS as an internal standard.
D2O was added to confirm the exchangeable protons.
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teins at their maximum absorption peaks (280 nm).
These hyperchromic effects were evident for the suc-
cessful conjugation of LND with both BSA and KLH.
The degree of conjugation of drug with both BSA and
KLH was determined spectrophotometrically according
to the method described by Habeeb [31]. The percen-
tages of LND residues in LND-BSA and LND-KLH con-
jugates were found to be 36.52 and 24.85%, respectively.Preparation and characterization of anti-LND antibody
Because of the high immunogenicity of KLH protein
[36], LND-KLH conjugate was selected as immunogen
for immunization of animals and LND-BSA conjugate
was selected for immobilization onto the microwell
plates in the ELISA. To monitor the progress of the im-
mune response of the rabbits and confirm that they were
sufficiently immunized, serum samples were collected
from the rabbits on the fourth to seventh days after each
immunization, and were analyzed by the direct ELISA
[32]. As shown in Figure 5A, the titers of the antisera
(indicated by the absorbance values) increased with the
repetitive immunizations. As well, it was observed that
the reactivity of the produced antibodies to the immobi-
lized protein (BSA) was comparable to that before
immunization (Figure 5B). These data indicated the spe-
cificity of the raised antibodies to the LND residues in
the immobilized LND-BSA, but not BSA molecules. The
measured small absorbance values were attributed to theFigure 4 Absorption spectra of G-LND (50 μg/mL; 1) and equal
concentrations (0.5 mg/mL) of BSA (2) and LND-BSA conjugate
(3). Concentration of LND-BSA conjugate was determined as BSA
protein. Concentrations were prepared in phosphate buffered saline.nonspecific binding. Although, all rabbits responded well
to the repetitive immunizations, however in order to
select the most appropriate animal for scarifying and
collecting the total sera, the affinity of these antisera
from all animals were checked by competitive ELISA as
described above. As shown in Figure 6, the serum from
rabbit No. 2 shows the highest affinity (lowest IC50) for
LND, therefore this rabbit was scarified and its total sera
were collected as crude anti-LND antibody, and it was
purified by affinity chromatography on protein A column.Purification of anti-LND antibody
The immunoglobulin fraction of the antibody specific to
LND was isolated from the crude serum sample of rabbit
No. 2 by precipitation with saturated ammonium
sulphate solution followed by purification on protein A
column using affinity chromatography. Protein A was
considered in this study based on its efficient binding to
wide range of immunoglobulins, and the easy elution of
these antibodies by mild chromatographic conditions
[37]. For purification of the antibody, serum sample was
applied onto the protein A column that has been equili-
brated with the immunoglobulin-binding buffer (glyci-
nate buffer of pH 8.7), and the eluent was fractionated.
The elution of the unbound UV-absorbing species was
monitored by measuring the absorbances of the fractions
at 280 nm. After complete elution of the UV absorbing
unbound species (Figure 7A), the immunoglobulin-
eluting buffer (citrate buffer of pH 3) was applied to
elute the immunoglobulin fraction that has been bound
to the protein A (Figure 7B). To confirm the binding of
the anti-LND antibody to the protein A by glycinate
buffer, and its elution with citrate buffer, the immunor-
eactivity of each fraction was tested by the direct ELISA
using LND-BSA conjugate as an immobilized antigen.
The very weak immunoreactivity of the fractions
obtained while applying glycinate buffer indicated that
most of the immunoglobulins were bound to the pro-
tein A (Figure 7C). As well, the high immunoreactivity
of fractions obtained while applying the citrate buffer
indicated the efficient elution of the immunoreactive
immunoglobulins by the citrate buffer (Figure 7D), and
most of the bound immunoglobulins were eluted in the
fractions No. 3–7. These fractions were collected,
pooled and dialyzed against PBS to remove the salts of
buffer solution. The protein concentration of the puri-
fied antibody was determined by BCA kit according to
the procedures recommended by the manufacturer.
Figure 5 Monitoring the immune response of rabbits immunized with LND-KLH. Microwell plates were coated with LND-BSA (panel A) and
BSA (panel B). Antiserum samples after different consecutive immunizations were allowed to bind to the immobilized antigen (BSA and
LND-BSA). Detailed procedures and signals were generated as described by Darwish et al. [32].
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antibody
In order to ascertain that the immunoreactivity of the
anti-LND antibody did not affected by buffer changes
during its purification by protein A column chromatog-
raphy, titration of anti-LND versus a fixed concentration
of the solid phase LND-BSA was carried. It was found
that the binding, indicated by absorbances, increases as
the antibody concentration increases (Figure 8). This
proved that the immunoreactivity of the antibody hasFigure 6 Affinity of antisera from rabbits No. 1 (●), No. 2 (○),
No. 3 (▲), and No.4 (♦) for LND. LND-BSA was coated onto the
microwell plates. Antiserum samples were mixed with LND and
transferred into the microwells. Competitive binding reaction was
allowed to proceed and the signals were generated as described by
Darwish et al. [32].not been affected during its purification. In addition, this
titration gave the optimum limiting concentration of the
antibody that can be used for effective competition be-
tween free LND (as competitor in the test sample) and
immobilized LND (LND-BSA coated onto the plate
wells), The limited (not saturating) antibody concentra-
tion that gave 1–1.5 absorbance unit (in the direct
ELISA) was 1 μg/mL (Figure 8). This concentration was
used in assessment of the specificity of the anti-LND
antibody by the competitive ELISA.
The specificity of the antibody was determined by car-
rying out the competitive assay using dexamethasone
that is administered in combined therapy with LND
[38], as a competitor. It was found that dexamethasone
does not show any immunoreactivity with the anti-LND
antibody. In conclusion, this antibody will be useful for
the establishment of a specific immunoassay system for
accurate determination of plasma concentrations of
LND. Optimization of the assay conditions, validation of
the method, and clinical applications are currently going
on in our laboratory, and the results will be published
elsewhere.
Conclusions
The present study described the synthesis of N-glutaryl
LND as a hapten, and the preparation of a highly spe-
cific polyclonal antibody against LND. The antibody
recognizes LND with high affinity. The high specificity
and affinity of the produced antibody enables the
Figure 7 Purification of anti-LND antibody from rabbit serum by protein A column affinity chromatography. (A) and (B) are the binding
and elution profiles of protein A column chromatography, respectively. (C) and (D) are immunoreactivity of the fractions eluted from protein A
column to the immobilized LND-BSA, determined by the direct ELISA.
Figure 8 Titration of the purified anti-LND antibody versus
immobilized LND-BSA conjugate.
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assay system for the accurate determination of LND in
plasma. The method is expected to contribute to the
therapeutic monitoring and pharmacokinetic studies of
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